knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 22:04:36 - browse：58

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Future doctors should be trained to promote social change

explore

WSS

Baby aspirin cuts fat buildup in liver disease patients, in small study

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Senators push IRS to launch nonprofit hospital probe

Asbestos, a deadly carcinogen, banned by EPA

Virtual Event: March of the Biosimilars

Methadone treatment changes are coming. Do they go far enough?

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Hepatitis C has a cure — but many Americans still lack access to it

Biden administration begins canceling student loan debt for 804,000 borrowers

Medical leaders decry Supreme Court decision on affirmative action

Schizophrenia gene found to be linked to cells' energy dysfunction

United colonoscopy coverage change 'may cost lives,' doctors say

Physicians and social media: If you see something, say something?

How one medical school became remarkably diverse

Health AI adoption puts security, privacy startups on investors' radar

The high cost of giving birth even with insurance

Methadone treatment changes are coming. Do they go far enough?

hotspot

Judge sides with young activists in first

Neuroscience’s long legacy of racism

Mark Cuban is blaming the wrong people for high drug costs

Nurses recount patients attacks

BMS, looking to build heart drug business, turns to AI for diagnosis

Bird flu researchers hone in on Finland’s mink farms

hotspot

explore

Wikipedia

knowledge